NCT02255409 - Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 | Biotech Hunter

Enrollment

607

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Influenza

Interventions

BIOLOGICAL

Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)

1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months

BIOLOGICAL

non-adjuvanted Quadrivalent Influenza Vaccine (QIV)

1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months

Trial Locations (28)

13901

Binghamton

20520

Turku

28100

Pori

32935

Melbourne

33100

Tampere

40291

Louisville

45406

Dayton

67010

Augusta

67100

Kokkola

67114

Newton

68005

Bellevue

70006

Metairie

76135

Fort Worth

76904

San Angelo

77375

Tomball

78705

Austin

80920

Colorado Springs

84088

West Jordan

84109

Salt Lake City

84121

Salt Lake City

84124

Salt Lake City

91706

San Gabriel

92103

San Diego

02230

Espoo

00100

Helsinki

00930

Helsinki

04400

Järvenpää

01300

Vantaa

All Listed Sponsors

lead

Seqirus

INDUSTRY